beta-phosphonopropionic acid has been researched along with Osteoporosis in 2 studies
beta-phosphonopropionic acid: structure
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation." | 3.76 | Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. ( Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feder, D | 1 |
| Kan, MW | 1 |
| Hussein, WM | 1 |
| Guddat, LW | 1 |
| Schenk, G | 1 |
| McGeary, RP | 1 |
| McKenna, CE | 1 |
| Kashemirov, BA | 1 |
| Błazewska, KM | 1 |
| Mallard-Favier, I | 1 |
| Stewart, CA | 1 |
| Rojas, J | 1 |
| Lundy, MW | 1 |
| Ebetino, FH | 1 |
| Baron, RA | 1 |
| Dunford, JE | 1 |
| Kirsten, ML | 1 |
| Seabra, MC | 1 |
| Bala, JL | 1 |
| Marma, MS | 1 |
| Rogers, MJ | 1 |
| Coxon, FP | 1 |
2 other studies available for beta-phosphonopropionic acid and Osteoporosis
| Article | Year |
|---|---|
Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis.
Topics: Acid Phosphatase; Animals; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibito | 2019 |
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Surv | 2010 |